Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders

Brenipatide showed a mean half-life ranging between 9.08 days and 12.5 days, with the longer half-life seen in participants given the highest dose of the drug at 4.5 mg.

The post Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders appeared first on GEN - Genetic Engineering and Biotechnology News.